fenofibric acid has been researched along with simvastatin in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 8 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Crook, MA; Lumb, PJ; Semra, YK; Wierzbicki, AS | 1 |
| Burhenne, J; Ehrhardt, M; Haefeli, WE; Lindenmaier, H; Weiss, J | 1 |
| Bays, HE; Buttler, SM; Davidson, MH; Jones, PH; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC | 1 |
| Buttler, SM; Kelly, MT; Mohiuddin, SM; Pepine, CJ; Setze, CM; Sleep, DJ; Stolzenbach, JC | 1 |
| Kelly, MT; Kipnes, MS; Lele, A; Rhyne, JM; Roth, EM; Setze, CM; Sleep, DJ; Stolzenbach, JC | 1 |
| Cusi, K; Davidson, MH; Jones, PH; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC; Thakker, K | 1 |
| Carlson, DM; Gold, A; Jones, PH; Kelly, MT; McKenney, JM; Roth, EM; Setze, CM; Stolzenbach, JC; Williams, LA | 1 |
| Bays, HE; Kelly, MT; McKenney, JM; Obermeyer, K; Roth, EM; Setze, CM; Sleep, DJ; Thakker, KM | 1 |
| Ballantyne, CM; Jones, PH; Kelly, MT; Lele, A; Setze, CM; Stolzenbach, JC; Thakker, KM | 1 |
| Filippatos, TD | 1 |
| Ballantyne, CM; Belmont, JW; Brautbar, A; Keinan, A; Ma, L | 1 |
2 review(s) available for fenofibric acid and simvastatin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
A review of time courses and predictors of lipid changes with fenofibric acid-statin combination.
Topics: Atorvastatin; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2012 |
8 trial(s) available for fenofibric acid and simvastatin
| Article | Year |
|---|---|
High-dose atorvastatin therapy in severe heterozygous familial hypercholesterolaemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholestyramine Resin; Drug Administration Schedule; Drug Combinations; Fenofibrate; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Middle Aged; Pyrroles; Simvastatin; Triglycerides | 1998 |
Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme.
Topics: Analysis of Variance; Atorvastatin; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Prospective Studies; Pyrimidines; Pyrroles; Research Design; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome | 2008 |
Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study.
Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Humans; Hypolipidemic Agents; Male; Middle Aged; Simvastatin; Young Adult | 2009 |
Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension study.
Topics: Adult; Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, VLDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2010 |
Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Female; Fenofibrate; Fluorobenzenes; Humans; Hypercholesterolemia; Hypertriglyceridemia; Liver; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2010 |
The effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia.
Topics: Dyslipidemias; Fenofibrate; Hypolipidemic Agents; Metabolic Syndrome; Simvastatin | 2010 |
Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglycerides.
Topics: Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2011 |
Interaction between SNPs in the RXRA and near ANGPTL3 gene region inhibits apoB reduction after statin-fenofibric acid therapy in individuals with mixed dyslipidemia.
Topics: Angiopoietin-Like Protein 3; Angiopoietin-like Proteins; Angiopoietins; Apolipoproteins; Apolipoproteins B; Atorvastatin; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Polymorphism, Single Nucleotide; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2012 |
2 other study(ies) available for fenofibric acid and simvastatin
| Article | Year |
|---|---|
Influence of lipid lowering fibrates on P-glycoprotein activity in vitro.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cells, Cultured; Dihydroergocryptine; Fenofibrate; Humans; Hypolipidemic Agents; Simvastatin; Swine; Transfection | 2004 |
Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
Topics: Aged; Atorvastatin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2010 |